Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy
Sponsor: CSL Behring
Terminated
due to lack of efficacy
Other terminated trials from CSL Behring
Other Oral Mucositis trials with similar outcome
This PHASE2 trial investigates Oral Mucositis and is currently terminated or withdrawn. CSL Behring leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — May 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSL Behring
For direct contact, visit the study record on ClinicalTrials.gov .